Clinical Trial Detail

NCT ID NCT02756962
Title Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

acute myeloid leukemia

Therapies

Midostaurin

Cytarabine

Age Groups: adult

Additional content available in CKB BOOST